NeoAg-specific Th1 cells were detected 9 days post tumor inoculation and their frequency within the tdLN rapidly declined from approximately 25% to approximately 3% of NeoAg-specific CD4+ cells over time regardless of therapeutic intervention. This evidence concerns the gene CD4 and neoplasm.